175 related articles for article (PubMed ID: 22212431)
1. AVE8134, a novel potent PPARα agonist, improves lipid profile and glucose metabolism in dyslipidemic mice and type 2 diabetic rats.
Schäfer HL; Linz W; Falk E; Glien M; Glombik H; Korn M; Wendler W; Herling AW; Rütten H
Acta Pharmacol Sin; 2012 Jan; 33(1):82-90. PubMed ID: 22212431
[TBL] [Abstract][Full Text] [Related]
2. The peroxisome proliferator-activated receptor-alpha (PPAR-alpha) agonist, AVE8134, attenuates the progression of heart failure and increases survival in rats.
Linz W; Wohlfart P; Baader M; Breitschopf K; Falk E; Schäfer HL; Gerl M; Kramer W; Rütten H
Acta Pharmacol Sin; 2009 Jul; 30(7):935-46. PubMed ID: 19503102
[TBL] [Abstract][Full Text] [Related]
3. A peroxisome proliferator-activated receptor alpha/gamma dual agonist with a unique in vitro profile and potent glucose and lipid effects in rodent models of type 2 diabetes and dyslipidemia.
Reifel-Miller A; Otto K; Hawkins E; Barr R; Bensch WR; Bull C; Dana S; Klausing K; Martin JA; Rafaeloff-Phail R; Rafizadeh-Montrose C; Rhodes G; Robey R; Rojo I; Rungta D; Snyder D; Wilbur K; Zhang T; Zink R; Warshawsky A; Brozinick JT
Mol Endocrinol; 2005 Jun; 19(6):1593-605. PubMed ID: 15831517
[TBL] [Abstract][Full Text] [Related]
4. PPARα ligand, AVE8134, and cyclooxygenase inhibitor therapy synergistically suppress lung cancer growth and metastasis.
Wu L; Wang W; Dai M; Li H; Chen C; Wang D
BMC Cancer; 2019 Dec; 19(1):1166. PubMed ID: 31791289
[TBL] [Abstract][Full Text] [Related]
5. Effects of combined PPARgamma and PPARalpha agonist therapy on reverse cholesterol transport in the Zucker diabetic fatty rat.
Tanabe J; Tamasawa N; Yamashita M; Matsuki K; Murakami H; Matsui J; Sugimoto K; Yasujima M; Suda T
Diabetes Obes Metab; 2008 Sep; 10(9):772-9. PubMed ID: 17970759
[TBL] [Abstract][Full Text] [Related]
6. Synergistic improvement in insulin resistance with a combination of fenofibrate and rosiglitazone in obese type 2 diabetic mice.
Choi WS; Lee JJ; Kim Y; Kim IS; Zhang WY; Myung CS
Arch Pharm Res; 2011 Apr; 34(4):615-24. PubMed ID: 21544727
[TBL] [Abstract][Full Text] [Related]
7. The effect of dual PPAR alpha/gamma stimulation with combination of rosiglitazone and fenofibrate on metabolic parameters in type 2 diabetic patients.
Seber S; Ucak S; Basat O; Altuntas Y
Diabetes Res Clin Pract; 2006 Jan; 71(1):52-8. PubMed ID: 16009445
[TBL] [Abstract][Full Text] [Related]
8. KDT501, a derivative from hops, normalizes glucose metabolism and body weight in rodent models of diabetes.
Konda VR; Desai A; Darland G; Grayson N; Bland JS
PLoS One; 2014; 9(1):e87848. PubMed ID: 24498211
[TBL] [Abstract][Full Text] [Related]
9. LT175 is a novel PPARα/γ ligand with potent insulin-sensitizing effects and reduced adipogenic properties.
Gilardi F; Giudici M; Mitro N; Maschi O; Guerrini U; Rando G; Maggi A; Cermenati G; Laghezza A; Loiodice F; Pochetti G; Lavecchia A; Caruso D; De Fabiani E; Bamberg K; Crestani M
J Biol Chem; 2014 Mar; 289(10):6908-6920. PubMed ID: 24451380
[TBL] [Abstract][Full Text] [Related]
10. Pharmacological profile of a novel, non-TZD PPARgamma agonist.
Chen X; Osborne MC; Rybczynski PJ; Zeck R; Yang M; Xu J; Zhou L; Cryan E; Tang Y; Demarest KT
Diabetes Obes Metab; 2005 Sep; 7(5):536-46. PubMed ID: 16050946
[TBL] [Abstract][Full Text] [Related]
11. Potent antidiabetic effects of rivoglitazone, a novel peroxisome proliferator-activated receptor-gamma agonist, in obese diabetic rodent models.
Kanda S; Nakashima R; Takahashi K; Tanaka J; Ogawa J; Ogata T; Yachi M; Araki K; Ohsumi J
J Pharmacol Sci; 2009 Oct; 111(2):155-66. PubMed ID: 19809220
[TBL] [Abstract][Full Text] [Related]
12. MD001, a Novel Peroxisome Proliferator-activated Receptor α/γ Agonist, Improves Glucose and Lipid Metabolism.
Kim SH; Hong SH; Park YJ; Sung JH; Suh W; Lee KW; Jung K; Lim C; Kim JH; Kim H; Park KS; Park SG
Sci Rep; 2019 Feb; 9(1):1656. PubMed ID: 30733541
[TBL] [Abstract][Full Text] [Related]
13. P633H, a novel dual agonist at peroxisome proliferator-activated receptors alpha and gamma, with different anti-diabetic effects in db/db and KK-Ay mice.
Chen W; Zhou XB; Liu HY; Xu C; Wang LL; Li S
Br J Pharmacol; 2009 Jul; 157(5):724-35. PubMed ID: 19422369
[TBL] [Abstract][Full Text] [Related]
14. Fenofibrate ameliorates diabetic and dyslipidemic profiles in KKAy mice partly via down-regulation of 11beta-HSD1, PEPCK and DGAT2. Comparison of PPARalpha, PPARgamma, and liver x receptor agonists.
Srivastava RA
Eur J Pharmacol; 2009 Apr; 607(1-3):258-63. PubMed ID: 19245804
[TBL] [Abstract][Full Text] [Related]
15. Dual PPARalpha /gamma activation provides enhanced improvement of insulin sensitivity and glycemic control in ZDF rats.
Brand CL; Sturis J; Gotfredsen CF; Fleckner J; Fledelius C; Hansen BF; Andersen B; Ye JM; Sauerberg P; Wassermann K
Am J Physiol Endocrinol Metab; 2003 Apr; 284(4):E841-54. PubMed ID: 12475752
[TBL] [Abstract][Full Text] [Related]
16. Improvement of glucose tolerance in Zucker diabetic fatty rats by long-term treatment with the dipeptidyl peptidase inhibitor P32/98: comparison with and combination with rosiglitazone.
Wargent E; Stocker C; Augstein P; Heinke P; Meyer A; Hoffmann T; Subramanian A; Sennitt MV; Demuth HU; Arch JR; Cawthorne MA
Diabetes Obes Metab; 2005 Mar; 7(2):170-81. PubMed ID: 15715890
[TBL] [Abstract][Full Text] [Related]
17. Rosiglitazone prevents the onset of hyperglycaemia and proteinuria in the Zucker diabetic fatty rat.
Smith SA; Lister CA; Toseland CD; Buckingham RE
Diabetes Obes Metab; 2000 Dec; 2(6):363-72. PubMed ID: 11225966
[TBL] [Abstract][Full Text] [Related]
18. Antidiabetic and hypolipidemic effects of a novel dual peroxisome proliferator-activated receptor (PPAR) alpha/gamma agonist, E3030, in db/db mice and beagle dogs.
Kasai S; Inoue T; Yoshitomi H; Hihara T; Matsuura F; Harada H; Shinoda M; Tanaka I
J Pharmacol Sci; 2008 Sep; 108(1):40-8. PubMed ID: 18776709
[TBL] [Abstract][Full Text] [Related]
19. A newly identified CG301269 improves lipid and glucose metabolism without body weight gain through activation of peroxisome proliferator-activated receptor alpha and gamma.
Jeong HW; Lee JW; Kim WS; Choe SS; Kim KH; Park HS; Shin HJ; Lee GY; Shin D; Lee H; Lee JH; Choi EB; Lee HK; Chung H; Park SB; Park KS; Kim HS; Ro S; Kim JB
Diabetes; 2011 Feb; 60(2):496-506. PubMed ID: 21270261
[TBL] [Abstract][Full Text] [Related]
20. A tailored therapy for the metabolic syndrome: the dual peroxisome proliferator-activated receptor-alpha/gamma agonist LY465608 ameliorates insulin resistance and diabetic hyperglycemia while improving cardiovascular risk factors in preclinical models.
Etgen GJ; Oldham BA; Johnson WT; Broderick CL; Montrose CR; Brozinick JT; Misener EA; Bean JS; Bensch WR; Brooks DA; Shuker AJ; Rito CJ; McCarthy JR; Ardecky RJ; Tyhonas JS; Dana SL; Bilakovics JM; Paterniti JR; Ogilvie KM; Liu S; Kauffman RF
Diabetes; 2002 Apr; 51(4):1083-7. PubMed ID: 11916929
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
